Literatur
- 1
Hoffmann J C, Zeitz M, Bischoff S C. et al .
Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus
conference by the German society of Digestive and Metabolic Diseases and the competence
network on inflammatory bowel disease.
Z Gastroenterol.
2004;
42
979-983
- 2
Travis S PL, Stange E F, Leman M. et al .
European-evidence-based consensus on the management of ulcerative colitis: Current
management.
J Crohns Colitis.
2008;
2
24-62
- 3
Tibble J A, Sigthorsson G, Foster R. et al .
Use of surrogate markers of inflammation and Rome criteria to distinguish organic
from nonorganic intestinal disease.
Gastroenterology.
2002;
123
450-460
- 4
Sugi K, Saitoh O, Hirata I. et al .
Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease:
comparison with other neutrophil-derived proteins.
Am J Gastroenterol.
1996;
91
27-934
- 5
Langhorst J, Elsenbruch S, Koelzer J. et al .
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel
diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and
clinical indices.
Am J Gastroenterol.
2008;
103
62-169
- 6
Kiesslich R, Fritsch J, Holtmann M. et al .
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia
and colon cancer in ulcerative colitis.
Gastroenterology.
2003;
124
880-888
- 7
Hurlstone D P, Cross S S, Drew K. et al .
An evaluation of colorectal endoscopic mucosal resection using high-magnification
chromoscopic colonoscopy: a prospective study of 1000 colonoscopies.
Endoscopy.
2004;
36
491-498
- 8
Rutter M D, Saunders B P, Schofield G. et al .
Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative
colitis.
Gut.
2004;
53
256
- 9
Marshall J K, Irvine E J.
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.
Aliment Pharmacol Ther.
1995;
9
293-300
- 10
Marteau P, Probert C S, Lindgren S. et al .
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy
alone in patients with extensive mild/moderate active ulcerative colitis: a randomised,
double blind, placebo controlled study.
Gut.
2005;
54
960-965
- 11
Sutherland L, Roth D, Beck P. et al .
Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.
Cochrane Database Syst Rev.
2000;
CD000543
- 12
Kamm M A, Sandborn W J, Gassull M. et al .
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Gastroenterology.
2007;
132
66-75
- 13
Turner D, Walsh C M, Steinhart A H. et al .
Response to corticosteroids in severe ulcerative colitis: a systematic review of the
literature and a meta-regression.
Clin Gastroenterol Hepatol.
2007;
5
103-110
- 14
Travis S P, Farrant J M, Ricketts C. et al .
Predicting outcome in severe ulcerative colitis.
Gut.
1996;
38
905-910
- 15
Lichtiger S, Present D H, Kornbluth A. et al .
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
N Engl J Med.
1994;
330
1841-1845
- 16
Ogata H, Matsui T, Nakamura M. et al .
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative
colitis.
Gut.
2006;
55
1255-1262
- 17
Arts J, D’Haens G, Zeegers M. et al .
Long-term outcome of treatment with intravenous cyclosporin in patients with severe
ulcerative colitis.
Inflamm Bowel Dis.
2004;
10
73-78
- 18
Fellermann K, Tanko Z, Herrlinger K R. et al .
Response of refractory colitis to intravenous or oral tacrolimus (FK506).
Inflamm Bowel Dis.
2002;
8
317-324
- 19
Järnerot G, Hertervig E, Friis-Liby I. et al .
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a
randomized, placebo-controlled study.
Gastroenterology.
2005;
128
1805-1811
- 20
Rutgeerts P, Sandborn W J, Feagan B G. et al .
Infliximab for induction and maintenance therapy for ulcerative colitis.
N Engl J Med.
2005;
353
2462-2476
- 21
Sandborn W, Sutherland L, Pearson D. et al .
Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease.
Cochrane Database Syst Rev.
2000;
CD000545
- 22
Kruis W, Schütz E, Fric P. et al .
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in
maintaining remission of ulcerative colitis.
Aliment Pharmacol Ther.
1997;
11
853-858
- 23
Rembacken B J, Snelling A M, Hawkey P M. et al .
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative
colitis: a randomised trial.
Lancet.
1999;
354
635-639
- 24
Kruis W, Fric P, Pokrotnieks J. et al .
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle
1917 is as effective as with standard mesalazine.
Gut.
2004;
53
1617-1623
- 25
Sands B E, Sandborn W J, Feagan B. et al .
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis
for active ulcerative colitis.
Gastroenterology.
2008;
135
400-409
- 26
Stremmel W, Merle U, Zahn A. et al .
Retarded release phosphatidylcholine benefits patients with chronic active ulcerative
colitis.
Gut.
2005;
54
966-971
PD Dr. med. Klaus Herrlinger
Zentrum für Innere Medizin I
Robert-Bosch Krankenhaus
Auerbachstraße 110
70376 Stuttgart
eMail: klaus.herrlinger@rbk.de
